415 related articles for article (PubMed ID: 28866656)
21. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways.
Zhao Y; Lee CK; Lin CH; Gassen RB; Xu X; Huang Z; Xiao C; Bonorino C; Lu LF; Bui JD; Hui E
Immunity; 2019 Dec; 51(6):1059-1073.e9. PubMed ID: 31757674
[TBL] [Abstract][Full Text] [Related]
22. Peptide Blocking CTLA-4 and B7-1 Interaction.
Podlesnykh SV; Abramova KE; Gordeeva A; Khlebnikov AI; Chapoval AI
Molecules; 2021 Jan; 26(2):. PubMed ID: 33419027
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy for cancer treatment.
Donátová K; Nováková E; Šupolíková M
Klin Onkol; 2022; 35(4):284-289. PubMed ID: 35989085
[TBL] [Abstract][Full Text] [Related]
24. Cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA-4-Ig) suppresses Staphylococcus aureus-induced CD80, CD86, and pro-inflammatory cytokine expression in human B cells.
Liu PC; Ssu CT; Tsao YP; Liou TL; Tsai CY; Chou CT; Chen MH; Leu CM
Arthritis Res Ther; 2020 Mar; 22(1):64. PubMed ID: 32228715
[TBL] [Abstract][Full Text] [Related]
25. Checkpoint Inhibitors in Dogs: Are We There Yet?
Giuliano A; Pimentel PAB; Horta RS
Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893123
[TBL] [Abstract][Full Text] [Related]
26. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.
Ma W; Gilligan BM; Yuan J; Li T
J Hematol Oncol; 2016 May; 9(1):47. PubMed ID: 27234522
[TBL] [Abstract][Full Text] [Related]
27. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
Fukuda T; Kamai T; Masuda A; Nukui A; Abe H; Arai K; Yoshida K
Cancer Med; 2016 Aug; 5(8):1810-20. PubMed ID: 27292320
[TBL] [Abstract][Full Text] [Related]
28. Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer.
Gaynor N; Crown J; Collins DM
Semin Cancer Biol; 2022 Feb; 79():44-57. PubMed ID: 32623044
[TBL] [Abstract][Full Text] [Related]
29. The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers.
Mestiri S; El-Ella DMA; Fernandes Q; Bedhiafi T; Almoghrabi S; Akbar S; Inchakalody V; Assami L; Anwar S; Uddin S; Gul ARZ; Al-Muftah M; Merhi M; Raza A; Dermime S
Biomed Pharmacother; 2024 Feb; 171():116095. PubMed ID: 38183744
[TBL] [Abstract][Full Text] [Related]
30. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
[TBL] [Abstract][Full Text] [Related]
31. Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts.
Wang Y; Zhang H; Liu C; Wang Z; Wu W; Zhang N; Zhang L; Hu J; Luo P; Zhang J; Liu Z; Peng Y; Liu Z; Tang L; Cheng Q
J Hematol Oncol; 2022 Aug; 15(1):111. PubMed ID: 35978433
[TBL] [Abstract][Full Text] [Related]
32. Immunomodulatory Properties of Immune Checkpoint Inhibitors-More than Boosting T-Cell Responses?
Kuske M; Haist M; Jung T; Grabbe S; Bros M
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406483
[TBL] [Abstract][Full Text] [Related]
33. Control of Memory Phenotype T Lymphocyte Homeostasis: Role of Costimulation.
Panda AK; Kim YH; Shevach EM
J Immunol; 2022 Feb; 208(4):851-860. PubMed ID: 35039334
[TBL] [Abstract][Full Text] [Related]
34. Immune Checkpoint Inhibitors: Recent Clinical Advances and Future Prospects.
Banday AH; Abdalla M
Curr Med Chem; 2023; 30(28):3215-3237. PubMed ID: 35986535
[TBL] [Abstract][Full Text] [Related]
35. Cancer Immunotherapy: An Overview of Small Molecules as Inhibitors of the Immune Checkpoint PD-1/PD-L1 (2015-2021).
Baglini E; Salerno S; Barresi E; Marzo T; Settimo FD; Taliani S
Mini Rev Med Chem; 2022; 22(14):1816-1827. PubMed ID: 35176979
[TBL] [Abstract][Full Text] [Related]
36. Immune checkpoint: The novel target for antitumor therapy.
Jiang X; Liu G; Li Y; Pan Y
Genes Dis; 2021 Jan; 8(1):25-37. PubMed ID: 33569511
[TBL] [Abstract][Full Text] [Related]
37. Decreased Expression of Negative Immune Checkpoint VISTA by CD4+ T Cells Facilitates T Helper 1, T Helper 17, and T Follicular Helper Lineage Differentiation in GCA.
Hid Cadena R; Reitsema RD; Huitema MG; van Sleen Y; van der Geest KSM; Heeringa P; Boots AMH; Abdulahad WH; Brouwer E
Front Immunol; 2019; 10():1638. PubMed ID: 31379838
[TBL] [Abstract][Full Text] [Related]
38. The next generation of immunotherapy: keeping lung cancer in check.
Somasundaram A; Burns TF
J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
[TBL] [Abstract][Full Text] [Related]
39. CTLA-4 antibody ipilimumab negatively affects CD4
Rosskopf S; Leitner J; Zlabinger GJ; Steinberger P
Cancer Immunol Immunother; 2019 Aug; 68(8):1359-1368. PubMed ID: 31332464
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer.
Niyongere S; Saltos A; Gray JE
J Thorac Dis; 2018 Feb; 10(Suppl 3):S433-S450. PubMed ID: 29593889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
